Gilead Sciences Announces Third Quarter 2026 Financial Results
Business Wire•29/10/2026•16:02 ET
0
Key Highlights
- ➤2026 product sales rose 13% to $8.3 billion year-over-year
- ➤Full-year 2026 product-sales guidance raised to $31.0 billion-$31.3 billion
- ➤HIV product sales increased 18% to $6.2 billion in the third quarter
- ➤Biktarvy sales increased 10% to $4.1 billion year-over-year
- ➤2026 non-GAAP diluted loss guidance widened to $(1.20)-$(0.85) per share
Expert Statements
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences
“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences
“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences
“Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year.”
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences
“With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”
Gilead Sciences Announces Third Quarter 2026 Financial Results
Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion
Get started
Create a free account to read the full story.